Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Hannani D, et al. Among authors: klatzmann d. Cell Res. 2015 Feb;25(2):208-24. doi: 10.1038/cr.2015.3. Epub 2015 Jan 13. Cell Res. 2015. PMID: 25582080 Free PMC article.
A novel dendritic cell subset involved in tumor immunosurveillance.
Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Métivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L. Taieb J, et al. Among authors: klatzmann d. Nat Med. 2006 Feb;12(2):214-9. doi: 10.1038/nm1356. Epub 2006 Jan 29. Nat Med. 2006. PMID: 16444265
Human CD90 identifies Th17/Tc17 T cell subsets that are depleted in HIV-infected patients.
Guillot-Delost M, Le Gouvello S, Mesel-Lemoine M, Cheraï M, Baillou C, Simon A, Levy Y, Weiss L, Louafi S, Chaput N, Berrehar F, Kerbrat S, Klatzmann D, Lemoine FM. Guillot-Delost M, et al. Among authors: klatzmann d. J Immunol. 2012 Feb 1;188(3):981-91. doi: 10.4049/jimmunol.1101592. Epub 2011 Dec 19. J Immunol. 2012. PMID: 22184726
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.
Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L. Chaput N, et al. Among authors: klatzmann d. Oncoimmunology. 2013 Feb 1;2(2):e23080. doi: 10.4161/onci.23080. Oncoimmunology. 2013. PMID: 23525357 Free PMC article.
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Hannani D, et al. Among authors: klatzmann d. Cell Res. 2015 Mar;25(3):399-400. doi: 10.1038/cr.2015.28. Cell Res. 2015. PMID: 25732764 Free PMC article. No abstract available.
IL-2 antibodies in type 1 diabetes and during IL-2 therapy.
Churlaud G, Rosenzwajg M, Cacoub P, Saadoun D, Valteau-Couanet D, Chaput N, Pugliese A, Klatzmann D. Churlaud G, et al. Among authors: klatzmann d. Diabetologia. 2018 Sep;61(9):2066-2068. doi: 10.1007/s00125-018-4649-4. Epub 2018 Jun 2. Diabetologia. 2018. PMID: 29860627 No abstract available.
373 results